- Home
- LUCD vs SABA Comparison
LUCD vs SABA Comparison
Compare LUCD & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.16
Company Overview
Basic Information| Metric | LUCD | SABA |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 225.6M |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | LUCD | SABA |
|---|---|---|
| Price | $1.16 | $8.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 486.8K | 96.1K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $126.14 | N/A |
| Revenue Next Year | $138.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.95 | $7.96 |
| 52 Week High | $1.70 | $9.46 |
Technical Indicators
Market Signals| Indicator | LUCD | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 56.98 |
| Support Level | $1.01 | $7.97 |
| Resistance Level | $1.22 | $8.90 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 31.25 | 49.21 |
Price Performance
Historical Comparison LUCD
SABA
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.